Judging Obesity Drugs: Can Patient-Focused Statistics Bring Simplicity, Clarity?
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The odds ratio would be a simpler way to look at an obesity drug’s success in promoting 5% weight loss than the current three-step process, FDA’s statistical reviewer said in her assessment of Belviq’s efficacy.
You may also be interested in...
Arena Finds Antidote For Belviq’s Theoretical Risk Of Valvulopathy In Mechanistic Studies
Additional preclinical studies provided FDA with reassurance during a second-cycle review that lorcaserin was unlikely to trigger the valvular heart disease associated with dexfenfluramine and fenfluramine.
New Paradigm Would Open More Avenues To Obesity Drug Approval
Assessments of obesity drugs should look at their effects in patients grouped by health status and FDA should expand the universe of secondary endpoints available to assess benefits, a group of stakeholders says.
Orexigen On Quicker-Than-Expected Pace To Obtain Data Needed To Re-File NDA For Contrave
During its second quarter earnings call, the biotech said it sees recent FDA approvals of two other obesity drugs as a positive for its own prospects, but it is re-engaging with the agency on why it must perform a cardiovascular-outcomes trial prior to approval.